Want to join the conversation?
Biopharmaceutical company $MNK said its 4Q15 GAAP net income rose 10.2% to $90MM, or $0.76 per share from a year ago on acquired products and strong volume growth in its specialty brands segment. On an adjusted basis, diluted EPS was $1.84. Net sales were $882MM, up 31%, driven exclusively by volume, with overall price down.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.
$SPY can the rally continue? La Pen almost assured to lose makes me cautious about the results, not a place to panic. If 2400 is reached I'm selling my puts and going for broke. Happy hunting.